VGXI Inc., a contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, and National Resilience Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, have entered a strategic multi-year partnership in which VGXI will serve as a plasmid DNA manufacturer to support Resilience’s advanced therapy manufacturing programs.
 
VGXI’s ability to achieve rapid production cycles and short delivery times for a full spectrum of clinical and commercial products is expected to enhance Resilience’s efficiency and overall capacity to meet the growing demand in the Cell and Gene Therapy (CGT) sector. As part of the partnership, Resilience will also gain access to VGXI’s suite of analytics for cell banking, drug substance and drug product.
 
The multi-year partnership establishes an accelerated and quality-focused network to further Resilience’s mission of helping researchers make their novel therapies quickly, safely and at scale. Together, VGXI and Resilience are excited to team together to enhance their vital role in expanding patient access to transformative medicines.
 
Young Park, CEO of VGXI, expressed enthusiasm about the partnership, stating, “We are excited to collaborate with Resilience, a sterling CDMO in the cell and gene therapy space. This strategic alliance not only marks a milestone for both companies but also signifies our joint commitment to solving key supply chain challenges to accelerate the delivery of advanced therapies to patients in need.”

Related News